Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 1,653 · FY2023 1,050 · FY2024 1,880 — 3-yr total 4,583
Medinservi (სს კომპანია მედინსერვი) — a mid-size Georgian pharmaceutical importer/distributor (joint-stock company, ~196 employees). Revenue ~GEL 16–19m through 2017–2022, tapering toward 2024; ranked among Georgia's top-10 pharmaceutical importers (ranked ~9th by import value in 2010). A wholesale/import distributor, not a retail pharmacy.
Group parent — controls 2 companies · ownership
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| 10,404 | 11,424 | 10,858 | 11,074 | 11,465 | 11,029 | 11,068 | 10,392 | -0.0% | |
| 6,607 | 6,364 | 6,829 | 20,588 | 20,040 | 19,690 | 20,594 | 10,104 | +6.3% | |
| TOTAL ASSETS | 17,011 | 17,788 | 17,687 | 31,661 | 31,504 | 30,719 | 31,662 | 20,496 | +2.7% |
| 3,510 | 3,998 | 5,044 | 4,231 | 2,503 | 2,636 | 386 | 822 | -18.7% | |
| 2,047 | 2,372 | 668 | 501 | 213 | 0 | 0 | 0 | nmf | |
| TOTAL LIABILITIES | 5,558 | 6,370 | 5,711 | 4,732 | 2,717 | 2,636 | 386 | 822 | -23.9% |
| 11,453 | 11,418 | 11,976 | 26,929 | 28,788 | 28,083 | 31,276 | 19,674 | +8.0% | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt analysis | |||||||||
| Total Debt | 0 | 0 | 618 | 451 | 163 | 0 | 0 | 0 | -48.6% |
| Cash & Equivalents | 3,695 | 4,120 | 3,174 | 3,106 | 4,407 | 7,170 | 6,734 | 8,697 | +13.0% |
| Net Debt | 3,695 | 4,120 | 2,556 | 2,654 | 4,244 | 7,170 | 6,734 | 8,697 | +13.0% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.